Source comparison
CJC-1295 vs Tesamorelin: Full Comparison
Before selecting a GHRH analog for research protocols, compare the molecular, pharmacokinetic, and clinical variables that define each peptide's performance profile. This table consolidates the key differentiators. Molecular Structure 29-amino-acid GHRH analog
This comparison does not assign a generated winner or score.
- Before selecting a GHRH analog for research protocols, compare the molecular, pharmacokinetic, and clinical variables that define each peptide's performance profile. This table consolidates the key differentiators.
- Molecular Structure
- 29-amino-acid GHRH analog with Drug Affinity Complex (albumin-binding modification)
- 44-amino-acid GHRH analog with trans-3-hexenoic acid N-terminal modification
- CJC-1295's albumin binding extends half-life dramatically; Tesamorelin's fatty acid chain enhances receptor affinity but not duration
- Elimination Half-Life
- 6–8 days
- 26–38 minutes
- CJC-1295's extended half-life allows weekly dosing; Tesamorelin requires daily administration
- Typical Research Dose
- 30–60 mcg/kg weekly (approximately 2–4 mg per injection for 70 kg subject)
- 2 mg daily subcutaneous injection
- Dosing frequency is the primary logistical differentiator
- Peak GH Response
- Sustained 2- to 10-fold elevation lasting 5–7 days
- Acute 10–15 ng/mL peak within 30 minutes, baseline by 3–4 hours
- CJC-1295 amplifies natural pulses over days; Tesamorelin delivers sharp transient spikes
- IGF-1 Duration
- Elevated for 9–11 days post-injection
- Returns to baseline within 24 hours of missed dose
- CJC-1295 produces cumulative IGF-1 elevation; Tesamorelin requires daily dosing for sustained effect
- FDA Approval Status
- Not FDA-approved; research-grade compound only
- FDA-approved (Egrifta) for HIV-associated lipodystrophy
- Tesamorelin has regulatory clearance; CJC-1295 does not
- Published Clinical Endpoints
- Phase I/II data on GH and IGF-1 elevation; no Phase III body composition trials
- Phase III data showing 15–18% visceral fat reduction over 26 weeks in HIV lipodystrophy
- Tesamorelin has peer-reviewed efficacy data; CJC-1295 evidence is limited to early-phase studies
- The bottom line: CJC-1295 vs Tesamorelin is not a question of potency. Both peptides effectively stimulate GH release. The decision hinges on experimental design requirements, dosing logistics, and whether regulatory-grade clinical data is necessary for your research model.